Fisher Asset Management LLC lowered its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART – Free Report) by 15.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 396,798 shares of the life sciences company’s stock after selling 73,609 shares during the quarter. Fisher Asset Management LLC owned about 0.51% of Integra LifeSciences worth $17,281,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors also recently modified their holdings of IART. Raymond James & Associates increased its position in shares of Integra LifeSciences by 28.7% during the third quarter. Raymond James & Associates now owns 204,325 shares of the life sciences company’s stock valued at $7,803,000 after buying an additional 45,554 shares during the period. Strs Ohio increased its position in shares of Integra LifeSciences by 6.9% during the third quarter. Strs Ohio now owns 41,730 shares of the life sciences company’s stock valued at $1,593,000 after buying an additional 2,679 shares during the period. Advisor Partners II LLC purchased a new position in shares of Integra LifeSciences during the third quarter valued at about $241,000. Inspire Investing LLC increased its position in shares of Integra LifeSciences by 5.1% during the third quarter. Inspire Investing LLC now owns 8,004 shares of the life sciences company’s stock valued at $306,000 after buying an additional 392 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its position in shares of Integra LifeSciences by 451.9% during the third quarter. Allspring Global Investments Holdings LLC now owns 70,827 shares of the life sciences company’s stock valued at $2,705,000 after buying an additional 57,993 shares during the period. Hedge funds and other institutional investors own 84.78% of the company’s stock.
Integra LifeSciences Price Performance
Shares of IART opened at $28.89 on Monday. The firm has a fifty day simple moving average of $33.75 and a two-hundred day simple moving average of $38.44. The firm has a market cap of $2.27 billion, a PE ratio of 34.81, a P/E/G ratio of 0.87 and a beta of 1.17. The company has a current ratio of 3.45, a quick ratio of 2.18 and a debt-to-equity ratio of 0.94. Integra LifeSciences Holdings Co. has a 1-year low of $27.18 and a 1-year high of $51.12.
Analyst Ratings Changes
A number of brokerages have weighed in on IART. StockNews.com cut shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Tuesday, April 30th. Truist Financial cut their price objective on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating on the stock in a report on Friday, March 1st. JMP Securities cut their price objective on shares of Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating on the stock in a report on Thursday, February 29th. Finally, Citigroup upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price objective on the stock in a report on Wednesday, April 3rd. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $44.89.
View Our Latest Stock Analysis on Integra LifeSciences
About Integra LifeSciences
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Read More
- Five stocks we like better than Integra LifeSciences
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Brinker International Heats Up on Spicy Earnings Beat and Raise
- Investing in Travel Stocks Benefits
- Eli Lilly Gains on the GLP-1 Weight Loss Phenomenon
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report
Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Co. (NASDAQ:IART – Free Report).
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.